Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.76 |
| ▸ | RAB9A | P51151 | 8/20 | 0.76 |
| ▸ | POLB | P06746 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | HPGD | P15428 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952977 | 0.80 | ALDH1A1 (0.88) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL13154699 | 0.80 | ALDH1A1 (0.97) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2946296 | 0.80 | ALDH1A1 (0.71) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2951630 | 0.79 | ALDH1A1 (1.00) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2942486 | 0.79 | ALDH1A1 (1.00) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL13154701 | 0.78 | ALDH1A1 (0.97) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2951772 | 0.77 | RAB9A (0.71) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2950756 | 0.75 | ALDH1A1 (1.00) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL13154693 | 0.75 | ALDH1A1 (1.00) | ALDH1A1RAB9APOLBMAPTHPGD | |
| SCHEMBL2950818 | 0.75 | ALDH1A1 (1.00) | ALDH1A1RAB9APOLBMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-09-30 | — | — | US | disclosed |
| US-7754709-B2 | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds | SOLVAY PHARMACEUTICALS BV (NL) | 2010-07-13 | — | — | US | disclosed |
| US-7754709-B2 | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds | SOLVAY PHARMACEUTICALS BV (NL) | 2010-07-13 | — | — | US | disclosed |
| US-7754709-B2 | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds | SOLVAY PHARMACEUTICALS BV (NL) | 2010-07-13 | — | — | US | disclosed |
| EP-1635840-B1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| EP-1635840-B1 | THIOPHENEPYRIMIDINONES AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS | SOLVAY PHARM BV (NL) | 2008-07-23 | — | — | EP | disclosed |
| US-20080103131-A1 | Therapeutically Active Thiophenepyrimidinone Compounds and Their Use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-05-01 | — | — | US | disclosed |
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032778-A1 | Therapeutically active thiophenepyrimidinone compounds and their use | HSD17B1, HSD17B3, HSD17B2 | ALDH1A1 133/4885RAB9A 3542/4885POLB 2228/4885 |
| US-20100249106-A1 | Methods of Making and Using Therapeutically Active Thiophenepyrimidinone Compounds | HSD17B3, HSD17B1, HSD17B2 | ALDH1A1 139/4885RAB9A 4047/4885POLB 2368/4885 |
| US-20080103131-A1 | Therapeutically Active Thiophenepyrimidinone Compounds and Their Use | HSD17B1, HSD17B3, HSD17B2 | ALDH1A1 133/4885RAB9A 3542/4885POLB 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.